Modulation of SETDB1 activity by APQ ameliorates heterochromatin condensation, motor function, and neuropathology in a Huntington’s disease mouse model

The present study describes evaluation of epigenetic regulation by a small molecule as the therapeutic potential for treatment of Huntington’s disease (HD). We identified 5-allyloxy-2-(pyrrolidin-1-yl)quinoline (APQ) as a novel SETDB1/ESET inhibitor using a combined in silico and in vitro cell based...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Enzyme Inhib Med Chem
Egile Nagusiak: Hwang, Yu Jin, Hyeon, Seung Jae, Kim, Younghee, Lim, Sungsu, Lee, Min Young, Kim, Jieun, Londhe, Ashwini M., Gotina, Lizaveta, Kim, Yunha, Pae, Ae Nim, Cho, Yong Seo, Seong, Jihye, Seo, Hyemyung, Kim, Yun Kyung, Choo, Hyunah, Ryu, Hoon, Min, Sun-Joon
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Taylor & Francis 2021
Gaiak:
Research Paper
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8008885/
https://ncbi.nlm.nih.gov/pubmed/33771089
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/14756366.2021.1900160
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak